ABT vs. HIMS: Abbott Laboratories vs. Hims & Hers Health Stock Comparison

Company Profile

Abbott Laboratories (ABT) and Hims & Hers Health (HIMS) both fall under the Health Care Equipment & Services industry group, but ABT is classified in Health Care Equipment & Supplies while HIMS is classified in Health Care Providers & Services.

Abbott Laboratories (ABT) has more than two decades of public-market history since March 17, 1980, whereas Hims & Hers Health (HIMS) listed on September 13, 2019 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Hims & Hers Health (HIMS) has a highly aggressive beta of 2.42, indicating much higher sensitivity to broad-market moves, while Abbott Laboratories (ABT) is defensive at 0.59 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Hims & Hers Health (HIMS) reports a negative ROE of -2.66%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Abbott Laboratories (ABT) reports 10.58%, ranking against industry peers normally.

Hims & Hers Health (HIMS) reports a negative net margin of -0.56%, usually indicating a net loss over the period. Meanwhile Abbott Laboratories (ABT) reports 11.65%, ranking against industry peers normally.

Hims & Hers Health (HIMS) reports a negative operating margin of -7.90%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Abbott Laboratories (ABT) reports 14.71%, ranking against industry peers normally.

Profitability Metrics

Growth

Hims & Hers Health (HIMS) at 59.00% clears its industry range for revenue growth, far stronger top-line momentum than Abbott Laboratories (ABT) at 5.67%, which is closer to a typical peer reading.

Hims & Hers Health (HIMS) at -3.77% is around its peer norm for EPS growth, while Abbott Laboratories (ABT) at -51.31% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Both Abbott Laboratories (ABT) at 1.38 and Hims & Hers Health (HIMS) at 1.69 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Abbott Laboratories (ABT) at 0.63 is near its industry mid-range for debt-to-equity ratio, while Hims & Hers Health (HIMS) at 2.54 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Hims & Hers Health (HIMS) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Abbott Laboratories (ABT) reports a yield of 2.30%, ranking against industry peers normally.

Hims & Hers Health (HIMS) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Abbott Laboratories (ABT) reports a payout of 78.96%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Abbott Laboratories (ABT) trades at 35.00 times trailing earnings, ranked against its peers, while Hims & Hers Health (HIMS) has no P/E ratio this period.

On P/S ratio, both Abbott Laboratories (ABT) at 4.00 and Hims & Hers Health (HIMS) at 3.09 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Abbott Laboratories (ABT) at 3.65 sits near its industry’s typical P/B ratio, while Hims & Hers Health (HIMS) at 16.33 prices above its benchmark range — HIMS looks rich relative to book.

Valuation Metrics